Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 17;10(8):2873-2874.
doi: 10.1016/j.ekir.2025.06.019. eCollection 2025 Aug.

Obinutuzumab in Rituximab-Resistant Podocytopathies: A Single-Center Experience

Andrea Angeletti  1 , Gianluca Caridi  1 , Xhuliana Kajana  1 , Carolina Bigatti  1   2 , Agnese Spennacchio  1 , Decimo Silvio Chiarenza  1 , Gabriele Mortari  1 , Paolo Cravedi  2 , Enrico E Verrina  1
Affiliations

Obinutuzumab in Rituximab-Resistant Podocytopathies: A Single-Center Experience

Andrea Angeletti et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Response to obinutuzumab in rituximab-resistant podocytopathies. Proteinuria and serum albumin levels before and after obinutuzumab for each patient. In 3 of 6 patients, oral immunosuppressive drug was withdrawn after obinutuzumab: patient 1 stopped calcineurin inhibitor, as patient 3 and 5 who kept mycophenolate mofetil. ProtU, proteinuria; Pt. patient.
See this image and copyright information in PMC

References

    1. Noone D.G., Iijima K., Parekh R. Idiopathic nephrotic syndrome in children. Lancet. 2018;392:61–74. doi: 10.1016/S0140-6736(18)30536-1. - DOI - PubMed
    1. Hengel F.E., Dehde S., Lasse M., et al. Autoantibodies targeting nephrin in podocytopathies. N Engl J Med. 2024;391:422–433. doi: 10.1056/NEJMoa2314471. - DOI - PubMed
    1. Trachtman H., Laskowski J., Lee C., et al. Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. Am J Physiol Ren Physiol. 2021;321:F505–F516. doi: 10.1152/ajprenal.00041.2021. - DOI - PMC - PubMed
    1. Colucci M., Angeletti A., Zotta F., et al. Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently relapsing/steroid-dependent nephrotic syndrome. Kidney Int. 2023;104:577–586. doi: 10.1016/j.kint.2023.06.013. - DOI - PubMed
    1. Chan E.Y., Lin K.Y., Yap D.Y., Ma A.L. Obinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion. Pediatr Nephrol. 2025;40:711–714. doi: 10.1007/s00467-024-06570-8. - DOI - PMC - PubMed

LinkOut - more resources